- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of January 7
The Center for Biosimilars® recaps the top news for the week of January 7, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 7.
Number 5: Samsung Bioepis has announced that it will partner with biopharmaceutical company 3SBio to develop and commercialize multiple biosimilars in mainland China.
Number 4: The United Kingdom-based Patients Association recently released results of a survey and focus group that sought to understand patient needs in switching to biosimilars from reference products.
Number 3: At the J.P. Morgan Healthcare Conference, Coherus presented an overview of the company’s “branded approach” to selling its newly launched biosimilar pegfilgrastim, Udenyca.
Number 2: The Community Oncology Alliance recently formed a standing Biosimilars Committee aimed at educating providers.
Number 1: During the J.P. Morgan Healthcare Conference, Pfizer and Teva gave a look at their strategies for 2019 and beyond.
Finally, last week, our e-newsletter asked if new US policies to promote biosimilar insulins will help.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
